
You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
TGA presentation: Nanoparticle Therapeutics 2016, 20 October 2016
Presentation: Regulation of Nanomedicines by the Therapeutic Goods Administration
Disclaimer
These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.
The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.
Presentation
- Presented by: Anne Field, Toxicology Section, Scientific Evaluation Branch, Therapeutic Goods Administration
- Presented at: Nanoparticle Therapeutics 2016
- Presentation date: 20 October 2016
- Presentation summary: This presentation describes how nanomedicines are regulated in Australia, and summarises activities under the National Nanotechnology Strategy designed to gauge and build our ongoing regulatory capacity for nanotherapeutics (including sunscreens)
Transcript
Print version
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.